Researchers at National Health Insurance Service Ilsan Hospital Report Research in Biosensors (Antibody Detection in Healthcare Workers after Vaccination with Two Doses of the BNT162b2 or ChAdOx1 Vaccine): Biosensors

2023 JUN 15 (NewsRx) -- By a News Reporter-Staff News Editor at Vaccine Daily -- Investigators publish new report on biosensors. According to news reporting out of Goyang, South Korea, by NewsRx editors, research stated, “Due to the COVID-19 pandemic, from 2020, many pharmaceutical companies have developed vaccines. To determine the efficacy of AstraZeneca’s and Pfizer’s vaccines, which were the first and second vaccines to be approved in Korea, respectively, we developed a method to measure their antibody-generating efficacies using immunology analyzers and a rapid antibody test available in Korea.”

The news editors obtained a quote from the research from National Health Insurance Service Ilsan Hospital: “The antibody-stimulating efficacies of the Pfizer and AstraZeneca vaccines were evaluated using Centaur. XPT SARS-CoV-2 (Siemens Healthineers, Germany), Elecsys. Anti-SARS-CoV-2 S (Roche Diagnostics, Germany), and STANDARD F SARS-CoV-2 nAb FIA (SD Biosensor, Korea). Healthcare workers were enrolled in two groups: the Pfizer (121) and AstraZeneca (117) groups. Antibody levels were measured pre-vaccination, three weeks after vaccination, and 16 weeks after vaccination. The Pfizer group comprised 41 males and 80 females, while the AstraZeneca group comprised 38 males and 79 females. Antibody results were analyzed after excluding four individuals who had recovered from COVID-19. Between weeks 3 and 16, there was no significant difference (P= 0.5, 1.0) between the results of the Roche and Siemens antibody tests in the Pfizer vaccine group. However, the SD biosensor results comparing with the Roche and Siemens antibody tests at three weeks after the initial vaccination showed a significant difference (P < 0.0001).”

According to the news editors, the research concluded: “Analysis of the Roche antibody test results before, at three weeks, and at 16 weeks after the administration of the Pfizer and AstraZeneca vaccines revealed a statistically significant difference between before and at three weeks after the first injection (P < 0.0001). After two doses of the Pfizer and AstraZeneca vaccines, antibody formation was above the 90th percentile of the measurement range in all subjects.”

For more information on this research see: Antibody Detection in Healthcare Workers after Vaccination with Two Doses of the BNT162b2 or ChAdOx1 Vaccine. Annals of Clinical Microbiology, 2022,25(3):91-101. The publisher for Annals of Clinical Microbiology is Korean Society of Clinical Microbiology.

A free version of this journal article is available at https://doi.org/10.5145/ACM.2022.25.3.4.

Our news journalists report that additional information may be obtained by contacting Kyoung Ho Roh, Department of Laboratory Medicine, National Health Insurance Service Ilsan Hospital, Goyang, South Korea. Additional authors for this research include Heun Choi, HeeKyoung Choi, Miseon Yoon, Jongha Yoo, Yoonseon Park.

(Our reports deliver fact-based news of research and discoveries from around the world.)